Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Additionally, emerging therapeutic modalitiessuch as nanotechnology and EVbased therapieshave opened new avenues for precision treatment of AP
The pattern reads as surface-level acknowledgment rather than resolution
The scenarios below reflect pricing verified as of July 2026, after Ro's exit from compounded GLP-1s
EBITDA margin guidance of 30-32% going forward is conservative relative to the 33.6% delivered in FY26 management is building in a buffer for geopolitical uncertainty and the loss of PLI benefits
US$ 20.77
US$ 22.76
US$ 24.53
US$ 21.90
US$ 22.18
US$ 27.89
US$ 24.50
